Methenamine as prophylaxis for recurrent urinary tract infections: an overview of the ALTAR trial. Issue 12 (December 2022)

• Record Type: Journal Article
• Authors: Clarke, Chelsea; Harding, Christopher
• Is Part Of: Obstetrics, gynaecology & reproductive medicine. Volume 32:Issue 12(2022)
• Page Start: 289
• Page End: 290
• Publication Date: 2022-12
• Subjects: antimicrobial resistance -- prophylaxis -- urinary tract infection; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618
• DOI: 10.1016/j.ogrm.2022.09.004
• Languages: English
• ISSNs: 1751-7214

Abstract

Abstract: Current recommended treatment for recurrent uncomplicated urinary tract infections in women includes low-dose daily antibiotics. The UK Antimicrobial Resistance Strategy document underlines the importance of non-antibiotic preventive treatments for common infections such as UTIs. The ALTAR trial investigated the clinical effectiveness of one such non-antibiotic treatment, the urinary antiseptic Methenamine Hippurate in the context of a randomised, open-label, pragmatic, two-arm non-inferiority trial with the comparator of daily low-dose antibiotics. Non-inferiority was confirmed in this study and the authors recommend that it should now be considered as a first-line preventive treatment for recurrent uncomplicated urinary tract infections in women.